Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 10/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.54 |
| ▸ | SCN8A | Q9UQD0 | 10/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.45 |
| ▸ | EDNRA | P25101 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094422 | 1.00 | SCN1A (0.54) | SCN1ASCN5ASCN8AKDM4ESCN9A | |
| SCHEMBL30201091 | 0.83 | SCN1A (0.54) | SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL29835236 | 0.82 | SCN1A (0.59) | SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL31003503 | 0.82 | ALDH1A1 (0.55) | SCN1ASCN5ASCN8AKDM4ESCN9A | |
| SCHEMBL1094469 | 0.82 | SCN1A (0.56) | SCN1ASCN5ASCN8AKDM4ESCN9A | |
| SCHEMBL29482006 | 0.80 | SCN1A (0.50) | SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL20095732 | 0.80 | SCN1A (0.50) | SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL1095053 | 0.79 | EDNRA (0.55) | SCN1ASCN5ASCN8AKDM4ESCN9A | |
| SCHEMBL31258825 | 0.79 | EDNRA (0.55) | SCN1ASCN5ASCN8AKDM4ESCN9A | |
| SCHEMBL1094173 | 0.78 | POLB (0.55) | KDM4ESCN9AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | SCN1A 10/4885SCN5A 51/4885SCN8A 58/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | SCN1A 54/4885SCN5A 42/4885SCN8A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.